Prognosis prediction and immunotherapy optimisation for cryptogenic new-onset refractory status epilepticus

Area of Science:

• Neurology
• Immunology
• Clinical Medicine

Background:

• Cryptogenic new-onset refractory status epilepticus (cNORSE) lacks comprehensive understanding of clinical dynamics, prognostic factors, and treatment guidance.
• This study addresses the knowledge gap by presenting longitudinal clinical profiles and predictive factors for outcomes in cNORSE patients.

Purpose of the Study:

• To elucidate the longitudinal clinical dynamics and functional outcomes in patients with cNORSE.
• To identify predictive factors for outcomes and determine the optimal duration of immunotherapy in cNORSE.
• To establish a more standardized understanding and clinical decision-making for cNORSE.

Main Methods:

• Retrospective analysis of a prospective autoimmune encephalitis cohort at a national referral center.
• Inclusion of 74 patients diagnosed with cNORSE.
• Assessment of longitudinal functional scales, seizure frequency, antiseizure medications, duration of unconsciousness, immunotherapy, cytokine/chemokine profiles, and serial MRI scans.

Main Results:

• 83.8% of patients regained consciousness within 30 days; 50% achieved good outcomes (mRS ≤2) at 2 years.
• Poor 1-year outcomes (mRS ≥3) were predicted by mesial temporal lobe (mTL) and extra-mTL lesions on 3-month MRI, and prolonged unconsciousness (≥60 days).
• Optimal immunotherapy duration was suggested to be between 18 weeks and 1 year post-NORSE onset.

Conclusions:

• This study provides insights into the longitudinal clinical dynamics, functional outcomes, and prognostic factors in cNORSE patients.
• Findings highlight the importance of MRI findings and duration of unconsciousness for predicting outcomes.
• The study suggests an optimal immunotherapy duration, aiding in clinical decision-making for cNORSE management.